The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...

The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) to treat a range of solid tumor malignancies.

Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo Qvantig for ...

Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Solid Tumor.

On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...

Bristol Myers Squibb BMY announced that the European Commission has approved the combination of its blockbuster ...

US FDA approves Opdivo Qvantig injection, for subcutaneous use in most previously approved adult, solid tumour Opdivo indications: Princeton, New Jersey Monday, December 30, 2024, ...

BMSs Opdivo gains FDA approval for faster subcutaneous cancer treatment BMS secures FDA nod for rapid cancer treatment ...